344 related articles for article (PubMed ID: 31929122)
21. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
[TBL] [Abstract][Full Text] [Related]
22. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
[TBL] [Abstract][Full Text] [Related]
23. Amantadine ER (Gocovri
Hauser RA; Walsh RR; Pahwa R; Chernick D; Formella AE
Front Neurol; 2021; 12():645706. PubMed ID: 33841311
[No Abstract] [Full Text] [Related]
24. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O
Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664
[TBL] [Abstract][Full Text] [Related]
26. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
27. Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Paci C; Thomas A; Onofrj M
Neurol Sci; 2001 Feb; 22(1):75-6. PubMed ID: 11487209
[TBL] [Abstract][Full Text] [Related]
28. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
[TBL] [Abstract][Full Text] [Related]
29. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
[TBL] [Abstract][Full Text] [Related]
30. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Thomas A; Iacono D; Luciano AL; Armellino K; Di Iorio A; Onofrj M
J Neurol Neurosurg Psychiatry; 2004 Jan; 75(1):141-3. PubMed ID: 14707325
[TBL] [Abstract][Full Text] [Related]
31. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
[TBL] [Abstract][Full Text] [Related]
32. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
[TBL] [Abstract][Full Text] [Related]
33. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Wolz M; Löhle M; Strecker K; Schwanebeck U; Schneider C; Reichmann H; Grählert X; Schwarz J; Storch A
J Neural Transm (Vienna); 2010 Nov; 117(11):1279-86. PubMed ID: 20803300
[TBL] [Abstract][Full Text] [Related]
34. Extended-release amantadine for OFF-related dystonia in Parkinson's disease.
Espay AJ; Ostrem JL; Formella AE; Tanner CM
Parkinsonism Relat Disord; 2024 May; 122():106088. PubMed ID: 38461688
[TBL] [Abstract][Full Text] [Related]
35. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
[TBL] [Abstract][Full Text] [Related]
36. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
[TBL] [Abstract][Full Text] [Related]
37. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
38. Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Corvol JC; Durif F; Meissner WG; Azulay JP; Haddad R; Guimarães-Costa R; Mariani LL; Cormier-Dequaire F; Thalamas C; Galitzky M; Boraud T; Debilly B; Eusebio A; Houot M; Dellapina E; Chaigneau V; Salis A; Lacomblez L; Benel L; Rascol O;
Parkinsonism Relat Disord; 2019 Mar; 60():51-56. PubMed ID: 30297210
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Perez-Lloret S; Rascol O
J Neural Transm (Vienna); 2018 Aug; 125(8):1237-1250. PubMed ID: 29511826
[TBL] [Abstract][Full Text] [Related]
40. Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Marmol S; Feldman M; Singer C; Margolesky J
CNS Drugs; 2021 Nov; 35(11):1141-1152. PubMed ID: 34648150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
